GEVO

GEVO's headline FY2025 revenue of $161M (+849% YoY) looks explosive, but the jump is a step-change from the GevoND ethanol and GevoRNG operating assets, not durable organic growth — and it comes at a NEGATIVE gross margin of -7.1%. A company that loses money on the product itself, before a dollar of overhead, has no proven unit economics. Net loss did narrow to -$33.8M from -$78.6M, but the accumulated deficit is $834M and management states plainly in the 10-K: 'We expect to incur losses for the foreseeable future' and 'may never achieve' profitability.

The real story is the balance sheet and the funding gap. Cash fell 57% to $81.2M while long-term debt jumped 145% to $165M and current liabilities more than tripled (+222.6%) to $78.6M. Operating cash flow was -$13.4M and capex $30.1M, so the business consumed roughly $43M of cash in the year against $81M on hand. The filing is explicit that GEVO 'will require substantial additional financings' and has historically funded itself 'primarily through equity offerings and issuances of debt' — meaning shareholders face ongoing dilution or leverage just to keep the lights on and advance the pipeline.